K-numberK251122
Device nameTerragene® Bionova® BT20 Biological Indicator
ApplicantTerragene
Product codeFRC
Device classClass II
Decision dateAug 4, 2025
DecisionSubstantially Equivalent
Regulation880.2800
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Terragene® Bionova® BT20 Biological Indicator is a single-use self-contained biological indicator (SCBI) for routine monitoring of steam sterilization process efficacy. It contains Geobacillus stearothermophilus spores on a paper carrier and a glass ampoule with purple pH-indicator culture medium that turns yellow if live spores survive sterilization. Results are read after 24-hour incubation at 60°C.

Technological characteristics

The subject device is nearly identical to the predicate BT220 SCBI in construction (polypropylene tube, filter paper spore carrier, glass ampoule with pH indicator), organism type and spore population (≥10⁶ Geobacillus stearothermophilus ATCC 7953), resistance parameters (D-values at 121°C, 132°C, 135°C), incubation temperature (60±2°C), and shelf-life (2 years). The key difference is a reduced incubation readout time: 24 hours for BT20 versus 48 hours for BT220. The predicate also includes a fluorescence-based readout option via MUG substrate; BT20 relies on visual pH color change only.

Test standards cited

ISO 11138-1:2017, ISO 11138-3:2017, ISO 11138-8:2021, ISO 11140-1:2014, and FDA Guidance for Industry on Biological Indicator [510(k)] Submissions (October 2007) and Chemical Indicators (December 2003).

Substantial equivalence argument

The devices share identical intended use (steam sterilization monitoring across the same temperature and time cycles), same organism strain and spore burden, equivalent resistance characteristics and incubation conditions, and identical shelf-life. The chemical process indicator on the label is identical in ink, location, and visual interpretation. The only substantive difference—reduced incubation time from 48 to 24 hours—is supported by performance testing demonstrating ≥97% sensitivity across all partial sterilization cycles. Since the fundamental performance (same spores, same resistance, same recovery medium) is unchanged and the faster readout is validated to perform as well, the subject device does not raise new safety or effectiveness concerns.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →